Barbara Cornblatt

Barbara Cornblatt, Ph.D., M.B.A., Director of RAP Program

Professor of Psychiatry and Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine

“I am delighted to serve on the Board of AIM, which is focused on mental health issues in children, teens and young adults. The non-profit is providing resources for both raising awareness and for developing the best treatments, and possibly even prevention, of mental health problems in young people. Not treating these difficulties as early as possible leads to a dramatically reduced productivity and lowered satisfaction with life on an individual level and to rising public health costs for the broader society. Funding by AIM to improve individual health and well-being is critical in these times of shrinking resources. Of particular importance is funding for clinical studies involving youth at risk or early symptomatic populations that are focused on treatments to stop problems from getting worse. In the area of psychosis, I have directed the Recognition and Prevention (RAP) program for close to 20 years. Over that time, private foundation funding has enabled us to develop successful, cutting-edge treatment programs for adolescents considered to be at risk for psychosis. AIM will help to launch and expand many successful programs such as ours.” – Barbara Cornblatt, PhD

Dr. Cornblatt is a Professor of Psychiatry and Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine and the Director of the Recognition and Prevention (RAP) Program. For more than 20 years, she has focused on research concerned with the causes and treatment of serious mental illness. She founded and currently directs the Recognition and Prevention (RAP) program in New York, one of the longest-running centers for the prevention of serious mental illness in North America.

The RAP Program, which was opened in 1998, is specifically dedicated to treating early warning signs of serious mental illness in adolescents and young adults. Over 500 youngsters have participated in both the research and treatment components of this program. Early treatment in the RAP Clinic has been consistently associated with a high rate of clinical improvement.

Dr. Cornblatt has authored or co-authored over 200 scientific articles and book chapters, has given many scientific talks nationally and internationally to a variety of prestigious scientific organizations, hospitals, and consumer groups, and is the co-director of the International Prodromal Research Network which sponsors international collaborations and prevention studies. She is also a member of the North American Prodrome Longitudinal Study (NAPLS) consortium, one of the largest and most successful prevention collaborations worldwide. She recently received awards from the National Alliance on Mental Illness (NAMI Queens/Nassau) and from the Women’s Health Institute, Katz Women’s Hospital (Lorinda de Roulet Award) for the achievements of the RAP research program. The RAP program is supported by funding from the National Institute of Mental Health and has been funded by the Robert Wood Johnson Foundation and several additional private charitable foundations.